Viking Therapeutics (VKTX) Invested Capital: 2014-2025
Historic Invested Capital for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $713.0 million.
- Viking Therapeutics' Invested Capital fell 21.77% to $713.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $713.0 million, marking a year-over-year decrease of 21.77%. This contributed to the annual value of $880.3 million for FY2024, which is 152.65% up from last year.
- According to the latest figures from Q3 2025, Viking Therapeutics' Invested Capital is $713.0 million, which was down 10.36% from $795.5 million recorded in Q2 2025.
- Viking Therapeutics' 5-year Invested Capital high stood at $933.9 million for Q1 2024, and its period low was $134.1 million during Q1 2023.
- Moreover, its 3-year median value for Invested Capital was $795.5 million (2025), whereas its average is $658.1 million.
- Per our database at Business Quant, Viking Therapeutics' Invested Capital decreased by 29.01% in 2022 and then surged by 596.60% in 2024.
- Over the past 5 years, Viking Therapeutics' Invested Capital (Quarterly) stood at $201.9 million in 2021, then dropped by 28.02% to $145.3 million in 2022, then soared by 139.76% to $348.4 million in 2023, then soared by 152.65% to $880.3 million in 2024, then decreased by 21.77% to $713.0 million in 2025.
- Its Invested Capital was $713.0 million in Q3 2025, compared to $795.5 million in Q2 2025 and $846.9 million in Q1 2025.